While the selectivity of these drugs to specifically inhibit FOXM1 has yet to be determined, this set of FOXM1 inhibitors have compelling translational potential to one day be clinically tested in logical combination therapies against cancers driven by FOXM1. The gene discussed is FOXM1; the disease is cancer.